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Abstract 
Medicinal plants have been for long remedies for human diseases because they contain 
components of therapeutic value. The growing problem of antibiotic resistance by organisms 
demands the search for novel compounds from plant based sources. The present study was 
aimed at evaluating the bioactivity and phytochemical analysis of Hydnora africana on 
clinical and standard strains of Helicobacter pylori (PE 252C and ATCC 43526), Aeromonas 
hydrophila ATCC 35654, and Staphylococcus aureus NCT 6571 in an effort to identify 
potential sources of cheap starting materials for the synthesis of new drugs against these 
strains. Ethyl acetate, acetone, ethanol, methanol, and water crude extracts of H. africana 
were screened for activity against the test organisms using the agar well diffusion assay. The 
Minimum Inhibitory Concentration (MIC50) and Minimum Bactericidal Concentration 
(MBC) of the most potent extracts were determined by the microdilution method, followed 
by qualitative phytochemical analysis. Results were analyzed statistically by ANOVA one - 
way test. Different concentrations (200,100, 50mg/mL) of the methanol, acetone, ethanol and 
ethyl acetate extracts showed activity against S. aureus and A. hydrophila while for H. pylori, 
only methanol and ethyl acetate extracts were active; water showed no activity for all studied 
bacterial pathogens. Mean zone diameter of inhibition which ranged from 0-22mm were 
observed for all test bacterial pathogens and 14-17mm for ciprofloxacin. The activity of 
methanol and ethyl acetate extracts were statistically significant (P< 0.05) compared to all the 
other extracts. MIC50 and MBC ranged from 0.078 – 2.5mg/mL, 0.78-25mg/mL respectively 
for all tested bacterial pathogens. For ciprofloxacin, the MIC50 and MBC ranged from 
0.00976 – 0.078mg/mL and 0.098– 0.78mg/mL respectively. There was no statistically 
significant difference between extracts (methanol, acetone, ethanol, ethyl acetate) and the 
control antibiotic (ciprofloxacin) (P> 0.05). Qualitative phytochemical analysis confirmed the 
presence of alkaloids, saponins, steroids, tannins and flavonoids in the methanol, acetone, 
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ethanol and ethyl acetate extracts. The results demonstrate that H. africana may contain 
compounds with therapeutic potentials which can be lead molecules for semi-synthesis of 
new drugs.  
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CHAPTER ONE 
                                       1.1   INTRODUCTION 
Medicinal plants have long been recognised as remedies for human diseases because they 
contain components of therapeutic value (Nostro et al., 2000). The study of medicinal plants 
used in folklore remedies has attracted enormous scientific attention in finding solutions to 
the problems of multiple resistances to the existing synthetic antibiotics. 
It is estimated that plant materials are present in or have provided the models for about 50% 
of Western drugs and herbal remedies continue to play a role in the cure of diseases (Tabuti 
et al., 2003). In developing countries particularly in South Africa, low income families, 
especially those of small native communities use folk medicine for the treatment of common 
infections. These plants are ingested as decoctions, teas and juice preparations to treat 
respiratory infections (Gonzalez, 1980). They are also made into a poultice and applied 
directly on the infected wounds or burns by traditional healers (Cowan and Steel, 2004). 
However, these healers claim that their medicine is cheaper and more effective than modern 
medicine.  
They also claim that the medicinal plant Hydnora africana is more efficient to treat infectious 
diseases than synthetic antibiotics. It is therefore necessary to evaluate, scientifically the 
potential use of this plant for the treatment of infectious diseases caused by common bacterial 
pathogens. It can be a possible source for new potent antibiotics to which pathogen strains are 
not resistant (Fabricant and Farnsworth, 2001). The plant H. africana belongs to the family 
Hydnoracea. It is a parasitic plant found in the dry and semi-arid parts of the Succulent 
Karoo, Little Karoo, Eastern Cape Karoo, and the dry coastal thickets between the Eastern 
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Cape and KwaZulu-Natal (Asfaw et al., 1999).  Infusions and decoctions of the plant are used 
in folklore remedies for the treatment of ailments such as diarrhoea, dysentery, kidney and 
bladder complaints. Infusions are used as face wash to treat acne by the Xhosa people (Van 
wyk and Gericke, 2000). 
 The choice therefore of H. africana is based on ethnobotanical information and preliminary 
data obtained in our laboratory, to determine its bioactivity against both Gram negative and 
positive microorganisms, notably: Helicobacter pylori ATCC 43526, Aeromonas hydrophila 
ATCC 35654, Staphylococcus aureus NCT 6571 and local isolate of H. pylori PE 252C. 
1.1.1 Helicobacter pylori is a Gram-negative, microaerophilic bacterium that causes chronic 
inflammation of the inner lining of the stomach (gastritis) in humans. This bacterium is also 
the most common cause of ulcers worldwide.  They are also associated with stomach cancer 
and a rare type of lymphocytic tumor of the stomach called MALT lymphoma (Vaira, 2001). 
H. pylori infection is most likely acquired by ingesting contaminated food and water and 
through person- to- person contact (Chan et al., 2008). 
The infection is more common in crowded living conditions with poor sanitation (Ndip et al., 
2004; Dube et al., 2009). Once H. pylori is detected in patients with peptic ulcer, the normal 
procedure is to eradicate it and allow the ulcer to heal. The standard first-line therapy is a one 
week triple therapy consisting of the antibiotics amoxicillin and clarithromycin, and a proton 
pump inhibitor such as omeprazole (Mirbagheri et al., 2006). 
Eradication of the organism has been shown to result in ulcer healing, prevention of peptic 
ulcer recurrence and may also reduce the prevalence of gastric cancer in high-risk 
populations (Sepulveda and Coelho, 2002; Ndip et al., 2008; Tanih et al., 2010 ). An 
increasing number of infected individuals are found to harbour antibiotic-resistant strains 
(Ndip et al., 2008; Tanih et al., 2010). This results in initial treatment failure and requires 
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additional rounds of antibiotic therapy or alternative strategies such as a quadruple therapy, 
which adds a bismuth colloid (Vaira, 2001; Lwai-Lume et al., 2005).   The emerging 
resistance to antibiotics, especially metronidazole and amoxicillin limits their use in the 
treatment of infections (O’Gara et al., 2000; Smith et al., 2001; Sherif et al., 2004). 
1.1.2 Aeromonas hydrophila is a heterotrophic, Gram-negative, rod shaped bacterium, 
mainly found in areas with a warm climate. This bacterium can also be found in fresh, salt, 
marine, estuarine, chlorinated, and un-chlorinated water. It can survive in aerobic and 
anaerobic environments (Villari et al., 2003). 
When it enters the body of its victim, it travels through the bloodstream to the first available 
organ. It produces Aerolysin Cytotoxic Enterotoxin (ACT), a toxin that can cause tissue 
damage (Ormen and Ostensvik, 2001). Aeromonas hydrophila, Aeromonas caviae, and 
Aeromonas sobria are all considered to be ―opportunistic pathogens,‖ meaning they only 
infect hosts with weakened immune responses.  
A. hydrophila infections occur most during environmental changes, stressors, change in 
temperature, in contaminated environments, and when an organism is already infected with a 
virus or another bacterium (Borchardt et al., 2003). It can also be ingested through food 
products that have already been contaminated with the bacterium (Chauret et al., 2001; El-
Taweel and Shaban, 2001). It causes gastroenteritis, cellulitis, myonecrosis and eczema in 
humans. These diseases can affect anyone, but it occurs most in young children and people 
who have compromised immune systems or growth problems (Sautour et al., 2003). It can be 
eliminated using one percent sodium hypochlorite solution and two percent calcium 
hypochlorite solution. Antibiotic agents such as chloramphenicol, florenicol, tetracycline, 
sulfonamide, nitrofuran derivatives, and pyrodinecarboxylic acids are used to eliminate and 
control infection (Gavriel et al., 1998; Chauret et al., 2001; WHO, 2002).  
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1.1.3 Staphylococcus aureus is a facultatively anaerobic, Gram-positive coccus and is the 
most common cause of staphylococcal infections. It is a spherical bacterium, frequently part 
of the skin flora found in the nose, and on skin (Cosgrove et al., 2009). It can cause a range of 
illnesses from minor skin infections, such as pimples, impetigo, boils, cellulitis, folliculitis, 
carbuncles, scalded skin syndrome and abscesses, to life-threatening diseases such as 
pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome (TSS), bacteremia 
and sepsis (Kluytmans et al., 1997). Its incidence is from skin, soft tissue, respiratory, bone, 
joint, endovascular to wound infections. It is still one of the five most common causes of 
nosocomial infections, often causing postsurgical wound infections. 
The treatment of choice for S. aureus infection is penicillin; but in most countries, penicillin-
resistance is extremely common and first-line therapy is most commonly penicillinase-
resistant penicillin (for example, oxacillin or flucloxacillin). Combination therapy with 
gentamicin may be used to treat serious infections like endocarditis (Korzeniowski and 
Sande, 1982; Bayer et al., 1998) but its use is controversial because of the high risk of 
damage to the kidneys (Cosgrove et al., 2009). The duration of treatment depends on the site 
of infection and on severity (Neely and Maley, 2000). 
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1.2 STATEMENT OF THE PROBLEM 
Infectious diseases are the most common cause of morbidity, transience globally and are 
continually being observed to be a danger to the community. Microorganisms have gained 
resistance against antibiotics that were before used to treat infectious diseases. This drug 
resistance phenomenon is troublesome and merits attention. Recently, there has been great 
interest in controlling the growth of microorganisms by using natural antimicrobials. 
Medicinal plants are used as natural antimicrobials to treat bacterial pathogens (Ndip et al., 
2008) and have been shown to be effective against clinical isolates that have been studied so 
far (Samie et al., 2007). We have preliminary data on the methanol extracts of H. africana 
with anti H. pylori activity. However, to the best of our knowledge, H. africana has not been 
evaluated for its antimicrobial activity against A. hydrophila and S. aureus. There is therefore 
need to evaluate the potential of this plant in a bid to search for new lead molecules with 
antimicrobial activity against these pathogens. 
1.3 HYPOTHESIS  
H. africana can provide potent and cheap leads with antimicrobial activity against H. pylori, 
A. hydrophila and S. aureus. 
1.4 OVERALL OBJECTIVE 
The present study is aimed at evaluating the antimicrobial potential of the flower of H. 
africana on some selected bacterial pathogens.  
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1.4.1 Specific objectives  
The specific objectives of this study are to: 
1. Screen the extracts of H. africana for bioactivity against H. pylori, A. hydrophila and S. 
aureus. 
2. Determine the minimum inhibitory concentration (MIC) 
3. Determine the minimum bactericidal concentration (MBC)  
4. Identify the active compounds responsible for the antimicrobial properties of the 
extracts. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 HELICOBACTER PYLORI 
2.1.1 HISTORY AND MORPHOLOGY 
It has been known for more than a century that bacteria are present in the human stomach 
(Bizzozero, 1893). These bacteria were thought to be contaminants from digested food rather 
than true gastric colonizers. About 20 years ago, Barry Marshall and Robin Warren described 
the successful isolation and culture of a spiral bacterial species, later known as Helicobacter 
pylori (Warren and Marshall, 1983), from the human stomach. Self-ingestion experiments by 
Marshall (Marshall et al., 1985) and Morris (Morris and Nicholson, 1987) and later 
experiments with volunteers (Morris et al., 1991) demonstrated that these bacteria can 
colonize the human stomach, thereby inducing inflammation of the gastric mucosa.  
H. pylori is a gram-negative bacterium, measuring 2 to 4 μm in length and 0.5 to 1 μm in 
width. Although usually spiral-shaped, the bacterium can appear rod shaped (Kusters et al., 
2006). The organism has 2 to 6 unipolar, sheathed flagella of approximately 3 μm in length,  
which often carry a distinctive bulb at the end (O`toole et al., 2000). The flagella confer 
motility and allow rapid movement in viscous solutions such as the mucus layer overlying the 
gastric epithelial cells (O`toole et al., 2000; Kusters et al., 2006).  
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2.1.2 PATHOGENESIS AND CLINICAL MANIFESTATION 
To colonize the stomach, H. pylori must survive the acidic pH of the lumen and burrow into 
the mucus to reach its niche, close to the stomach's epithelial cell layer. The bacterium has 
flagella and moves through the stomach lumen and drills into the mucoid lining of the 
stomach (Ottemann and Lowenthal, 2002). Many bacteria can be found deep in the mucus, 
which is continuously secreted by mucous cells and removed on the luminal side. To avoid 
being carried into the lumen, H. pylori senses the pH gradient within the mucus layer by 
chemotaxis and swims away from the acidic contents of the lumen towards the more neutral 
pH environment of the epithelial cell surface (Schreiber et al., 2004). 
 This bacterium is also found on the inner surface of the stomach epithelial cells and 
occasionally inside epithelial cells (Petersen and Krogfelt, 2003). It produces adhesins which 
bind to membrane-associated lipids and carbohydrates and help it adhere to epithelial cells. It 
produces large amounts of the enzyme urease, molecules of which are localized inside and 
outside of the bacterium. Urease breaks down urea (which is normally secreted into the 
stomach) to carbon dioxide and ammonia which is converted into ammonium ion by taking 
hydrogen from water upon its breakdown into hydrogen and hydroxyl ions. Hydroxyl ions 
then react with carbon dioxide, producing bicarbonate which neutralizes gastric acid. The 
survival of H. pylori in the acidic stomach is dependent on urease. The ammonia that is 
produced is toxic to the epithelial cells, and, along with the other products of H. pylori 
including protease, vacuolating cytotoxin A (VacA), and certain phospholipases damages 
those cells (Smoot, 1997). 
Colonization of the stomach by H. pylori results in chronic gastritis, an inflammation of the 
stomach lining (Shiotani and Graham, 2002).  Duodenal and stomach ulcers result when the 
consequences of inflammation allow the acid and pepsin in the stomach lumen to overwhelm 
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the mechanisms that protect the stomach and duodenal mucosa from these caustic substances. 
The type of ulcer that develops depends on the location of chronic gastritis, which occurs at 
the site of H. pylori colonization (Dixon, 2000). The acidity within the stomach lumen affects 
the colonization pattern of H. pylori and therefore ultimately determines whether a duodenal 
or gastric ulcer will form. In people producing large amounts of acid, H. pylori colonizes the 
antrum of the stomach to avoid the acid-secreting parietal cells located in the corpus of the 
stomach (Kusters et al., 2006).   
The inflammatory response to the bacteria induces G cells in the antrum to secrete the 
hormone gastrin, which travels through the bloodstream to the corpus (Blaser and Atherton, 
2004). Gastrin stimulates the parietal cells in the corpus to secrete even more acid into the 
stomach lumen. Chronically increased gastrin levels eventually cause the number of parietal 
cells to also increase, further escalating the amount of acid secreted (Schubert and Peura, 
2008). The increased acid load damages the duodenum, and ulceration may eventually result. 
In contrast, gastric ulcers are often associated with normal or reduced gastric acid production, 
suggesting that the mechanisms that protect the gastric mucosa are defective (Schubert and 
Peura, 2008). H. pylori can also colonize the corpus of the stomach, where the acid-secreting 
parietal cells are located. However, chronic inflammation induced by the bacteria causes 
further reduction of acid production and, eventually, atrophy of the stomach lining, which 
may lead to gastric ulcer and increases the risk for stomach cancer (Suerbaum and Michetti, 
2002). 
2.1.2.1 Gastritis and gastric cancer 
Once infected with H. pylori, most persons remain asymptomatic. Some infected persons 
may even clear the infection, with seroreversion rates commonly reported to be in the range 
of 5% to 10%. It is not known if this seroreversion is spontaneous or results from elimination 
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of the organism by antibiotic agents used to treat other conditions (Everhart, 2000).  
However, the typical course of disease in infected patients begins with chronic superficial 
gastritis, eventually progressing to atrophic gastritis. This progression appears to be a key 
event in the cellular cascade that results in the development of gastric carcinoma (Morgner et 
al., 2000).  
Although H. pylori is associated with the development of adenocarcinoma of the antrum and 
body of the stomach, it is also clearly linked with gastric mucosa–associated lymphoid tissue 
(MALT) lymphomas (Zucca et al., 1998). H. pylori stimulates lymphocytic infiltration of the 
mucosal stroma; this infiltration may act as a focus for cellular alteration and proliferation, 
ultimately resulting in neoplastic transformation to lymphoma (Zucca et al., 1998). It appears 
that H. pylori also produces proteins that stimulate growth of lymphocytes in the early stages 
of neoplasia (Morgner et al., 2000).  
2.1.2.2 Peptic ulcer disease 
The relationship between H. pylori infection and peptic ulcer disease has been studied 
exhaustively, and it is now accepted that the organism is the major cause of peptic ulcer 
disease worldwide. Eradicating the infection can alter the natural course of peptic ulcer 
disease by dramatically reducing its recurrence rate in treated patients, compared with 
untreated patient. This reduction occurs in patients with duodenal and gastric ulcers who have 
no history of nonsteroidal anti-inflammatory drug use (Cohen, 2000). 
2.1.2.3 Nonulcer dyspepsia 
Nonulcer dyspepsia comprises a constellation of varied symptoms, including dysmotility-
like, ulcer-like, and reflux-like symptoms. Many possible causes have been suggested for 
nonulcer dyspepsia, including lifestyle factors, stress, altered visceral sensation, increased 
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serotonin sensitivity, alterations in gastric acid secretion and gastric emptying, and H. pylori 
infection (Olden and Drossman, 2000).  
2.1.2.4 Gastroesophageal reflux disease 
Much attention has been focused on the possible relationship between infection with H. 
pylori and gastroesophageal reflux disease (GERD) in its various manifestations (eg, 
esophagitis, Barrett’s esophagus). Some investigators have suggested a link between the 
presence of H. pylori and a decreased risk for developing esophagitis and Barrett’s esophagus 
(Loffeld et al., 2000). Studies have also indicated that certain strains of H. pylori, notably the 
CagA positive strains, may be protective against the development of Barrett’s esophagus 
(Vaezi et al., 2000).  
2.1.3 LABORATORY DIAGNOSIS 
Currently, there are several methods for detecting the presence of H. pylori infection, each 
having its own advantages, disadvantages, and limitations. Basically, the tests available for 
diagnosis can be separated according to whether or not endoscopic biopsy is necessary. 
Histologic evaluation, culture, polymerase chain reaction (PCR), and rapid urease tests are 
typically performed on tissue obtained at endoscopy (invasive tests) (Stenstorm et al., 2008). 
Alternatively, simple breath tests, serology, and stool assays are sometimes used, and trials 
investigating PCR amplification of saliva, feces, and dental plaque to detect the presence of 
H. pylori have been described (non-invasive tests) (Bravos and Gilman, 2000). 
2.1.3.1 Histology 
 Histologic evaluation has traditionally been the gold standard method for diagnosing H. 
pylori infection. The disadvantage of this technique is the need for endoscopy to obtain 
tissue. Limitations also arise at times because of an inadequate number of biopsy specimens 
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obtained or failure to obtain specimens from different areas of the stomach (Gatta et al., 
2003). In some cases, different staining techniques may be necessary, which can involve 
longer processing times and higher costs. However, histologic sampling does allow for 
definitive diagnosis of infection, as well as of the degree of inflammation or metaplasia and 
the presence/absence of MALT lymphoma or other gastric cancers in high-risk patients. 
2.1.3.2 Culture  
Because H. pylori is difficult to grow on culture media, the role of culture in diagnosis of the 
infection is limited mostly to research and epidemiologic considerations. In growing this 
organism, the media components should include an agar base, growth supplements e.g., sheep 
and horse blood or serum, and selective supplements containing antimicrobial compounds 
e.g., vancomycin or teicoplanin to inhibit gram-positive cocci; polymyxin, nalidixic acid, 
colistin, trimethoprim, or cefsulodin to inhibit gram-negative rods; and nystatin or 
amphotericin B to inhibit fungi (Ndip et al., 2004; Mégraud and Lehours, 2007). Although 
costly, time-consuming, and labor intensive, culture does have a role in antibiotic 
susceptibility studies and studies of growth factors and metabolism (Perez-Perez, 2000; Tanih 
et al., 2010). 
2.1.3.3 Polymerase chain reaction 
With the advent of PCR, many exciting possibilities emerged for diagnosing and classifying 
H. pylori infection. PCR allows identification of the organism in small samples with few 
bacteria present and entails no special requirements in processing and transport. Moreover, 
PCR can be performed rapidly and cost- effectively, and it can be used to identify different 
strains of H. pylori for pathogenic and epidemiologic studies. PCR has also been used in 
identifying H. pylori in samples of dental plaque, saliva, and other easily sampled tissues 
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(Smith et al., 2002; Samie et al., 2007). In addition, PCR can detect segments of H. pylori 
DNA in the gastric mucosa of previously treated patients. 
2.1.3.4 Rapid urease testing 
Rapid urease testing takes advantage of the fact that H. pylori is a urease-producing 
organism. Samples obtained on endoscopy are placed in urea-containing medium; if urease is 
present, the urea will be broken down to carbon dioxide and ammonia, with a resultant 
increase in the pH of the medium and a subsequent color change in the pH-dependent 
indicator. This test has the advantages of being inexpensive, fast, and widely available 
(Kaklikka et al., 2006). 
2.1.3.5 Urea breath test 
A urea breath test similarly relies on the urease activity of H. pylori to detect the presence of 
active infection. In this test, a patient with suspected infection ingests either 
14
C- labeled or 
13
C- labeled urea; 
13
C- labeled urea has the advantage of being nonradioactive and thus safer 
for children and women of childbearing age. Urease, if present, splits the urea into ammonia 
and isotope-labeled carbon dioxide; the carbon dioxide is absorbed and eventually expired in 
the breath, where it is detected. Besides being excellent for documenting active infection, this 
test is also valuable for establishing the absence of infection after treatment, an important 
consideration in patients with a history of complicated ulcer disease with bleeding or 
perforation (Oderda et al., 2001).  
2.1.3.6 Serologic tests 
In response to H. pylori infection, the immune system typically mounts a response through 
production of immunoglobulins to organism-specific antigens. These antibodies can be 
detected in serum or whole-blood samples. The presence of IgG antibodies to H. pylori can 
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be detected by use of a biochemical assay. Serologic tests offer a fast, easy, and relatively 
inexpensive means of identifying patients who have been infected with the organism 
(Kaklikka et al., 2006).  This method is also useful in identifying certain strains of more 
virulent H. pylori by detecting antibodies to virulence factors associated with more severe 
disease and complicated ulcers, gastric cancer, and lymphoma. 
2.1.3.7. Stool antigen testing 
Stool antigen testing is a methodology that uses an enzyme immunoassay to detect the 
presence of H. pylori antigen in stool specimens. A cost effective and reliable means of 
diagnosing active infection and confirming cure, such testing has a sensitivity and specificity 
comparable to those of other noninvasive tests (Ndip et al., 2004; Ricci et al., 2007).  
2.1.4 EPIDEMIOLOGY 
The prevalence of H. pylori shows large geographical variations. In various developing 
countries, more than 80% of the population is H. pylori positive, even at young ages (Perez-
Perez et. al, 2004; Ndip et al., 2004; Ndip et al., 2008). The prevalence of H. pylori in 
industrialized countries generally remains under 40% and is considerably lower in children 
and adolescents than in adults and elderly people (Ahmed et al., 2007). Within geographical 
areas, prevalence inversely correlates with socioeconomic status, in particular in relation to 
living conditions during childhood (Kuster et al., 2006). In Western countries, the prevalence 
of this bacterium is often considerably higher among first- and second-generation immigrants 
from the developing world (Tummuru et al., 1993; Perez-Perez et al., 2005). While the 
prevalence of H. pylori infection in developing countries remains relatively constant, it is 
rapidly declining in the industrialized world (Genta, 2002). The latter is thought to be caused 
by the reduced chances of childhood infection due to improved hygiene and sanitation and 
the active elimination of carriership via antimicrobial treatment. In developing countries, H. 
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pylori infection rates rise rapidly in the first 5 years of life and remain constantly high 
thereafter, indicating that the bacterium is acquired early in childhood (Fiedorek et al., 1991; 
Ndip et al., 2004). However, in industrialized countries the prevalence of infection is low 
early in childhood and slowly rises with increasing age. This increase results only to a small 
extent from H. pylori acquisition at later age. The incidence of new infections among adults in 
the Western world is less than 0.5% per year; the higher prevalence of infection among the 
elderly thus reflects a birth cohort effect with higher infection rates in the past (Genta, 2002; 
Asrat et al., 2004). The active elimination of H. pylori from the population and improved 
hygiene and housing conditions have resulted in a lower infection rate in children, which is 
reflected in the age distribution of this lifelong-colonizing bacterium (Roose Ndaal et al., 
1997; Rehnberg-Laiho et al., 2001). Overall, new infection more commonly occurs in 
childhood and lasts for life unless specifically treated. 
2.1.4.1 Transmission and sources of infection 
The exact mechanisms whereby H. pylori is acquired are largely unknown. The organism has 
a narrow host range and is found almost exclusively in humans and some nonhuman 
primates. It has on rare occasions been isolated from pet animals; thus, the presence of pets 
may be a risk factor for infection (Dore et al., 2001; Herbarth et al., 2001; Brown et al., 
2002). New infections are thought to occur as a consequence of direct human-to-human 
transmission, via either an oral-oral or fecal-oral route or both. H. pylori has been detected in 
saliva, vomitus, gastric refluxate, and feces (Ferguson et al., 1993; Ferguson et al., 1999; 
Leung et al., 1999; Parsonnet et al, 1999; Allaker et al., 2002; Kabir, 2004;  Sinha et al., 
2004), but there is no conclusive evidence for predominant transmission via any of these 
products. 
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Studies have reported that there was no clear increased risk for being a carrier of H. pylori 
among dentists, gastroenterologists, nurses, partners of an H. pylori-positive spouse, or 
visitors to a clinic for sexually transmitted diseases (Aoki et al., 2004). As a result of these 
and other investigations, it is generally believed that acquisition mostly occurs in early 
childhood, most likely from close family members (Kivi et al., 2003; Raymond et al., 2004; 
Konno et al., 2005; Rowland et al., 2006). Premastication of food by the parent is an 
uncertain risk factor for transmission (Delport et al., 2007). Childhood crowding in and 
outside the family are all positively associated with H. pylori prevalence (Goodman and 
Correa, 2000), whereas among adults crowding appears less important, with the exception of 
certain circumstances, such as among army recruits (Kyriazanos et al., 2001; Rowland et al., 
2006). Several studies have reported the presence of H. pylori DNA in environmental water 
sources (Sakamoto et al., 1989; Enroth and Engstrand, 1995; Hegarty et al., 1999; Dube et 
al., 2009), but this probably reflects contamination with either naked DNA or dead H. pylori 
organisms. There is only a single report indicating that H. pylori has been successfully 
cultured from water, but this involved wastewater and as such may well represent fecal 
contamination of the water source (Momba et al., 2005). Spread via fecal contaminants is 
supported by the occurrence of H. pylori infections among institutionalized young people 
during outbreaks of gastroenteritis (Laporte et al., 2004). Other possible sources include 
contaminated food, as H. pylori may survive briefly on refrigerated food (Perry et al., 2006); 
direct person-to-person transmission remains the most likely transmission route. 
 
 
 
17 
 
2.1.5 TREATMENT, RESISTANCE MECHANISMS, PREVENTION AND  b  b  b bbb   
bbbbCONTROL  
2.1.5.1 Treatment 
Once H. pylori is detected in patients with peptic ulcer, the normal procedure is to eradicate it 
and allow the ulcer to heal. The standard first-line therapy is a one week triple therapy 
consisting of a proton pump inhibitor such as omeprazole and the antibiotics clarithromycin 
and amoxicillin (Mirbagheri et al., 2006). Variations of the triple therapy have been 
developed over the years, such as using a different proton pump inhibitor, as with 
pantoprazole or rabeprazole, or replacing amoxicillin with metronidazole for people who are 
allergic to penicillin (Malfertheiner et al., 2007). Such a therapy has revolutionized the 
treatment of peptic ulcers and has made a cure to the disease possible; previously the only 
option was symptom control using antacids, H2-antagonists or proton pump inhibitors alone 
(Rauws and Tytagt, 1990; Graham et al., 1991). 
An increasing number of infected individuals are found to harbour antibiotic-resistant strains. 
This results in initial treatment failure and requires additional rounds of antibiotic therapy or 
alternative strategies such as a quadruple therapy, which adds a bismuth colloid (Fischbach 
and Evans, 2007; Stenstrom et al., 2008; Graham and Shiotoni, 2008). For the treatment of 
clarithromycin-resistant strains the use of levofloxacin as part of the therapy has been 
suggested (Perna et al., 2007; Hsu et al., 2008). 
2.1.5.2 Resistance mechanisms to antibiotics. 
H. pylori acquires resistance to all the antibiotics used in the treatment regimens by mutation 
(Me´graud and Lehours, 2007). The mechanism does not involve plasmids which could be 
transmitted horizontally but point mutations (nonsense, missense and silent mutations) which 
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are transmitted vertically; however, transformation may be possible if two strains are present 
simultaneously in the stomach. The consequence is a progressive increase in the resistance 
rate due to the selection pressure. As in many bacteria, drug efflux proteins can contribute to 
natural insensitivity to antibiotics and to emerging antibiotic resistance.  
Resistance to macrolides: Macrolides act by binding to ribosomes at the level of the peptidyl 
transferase loop of the 23S rRNA gene. Resistance of H. pylori to macrolides is a major cause 
of failure of eradication therapies. H. pylori resistance is the consequence of point mutations 
at two nucleotide positions, 2142 (A2142G and A2142C) and 2143 (A2143G), which lead to 
a conformational change and a decrease in macrolide binding (Occhialini et al., 1997; Li et 
al., 2007). 
Resistance to amoxicillin: Amoxicillin acts by interfering with peptidoglycan synthesis, 
especially by blocking transporters named penicillin binding proteins (PBP). The rare 
amoxicillin-resistant H. pylori strains harbour mutations on the pbp-1a gene. Amino acid 
substitution Ser-414_Arg appears to be involved, leading to a blockage of penicillin transport 
(Van-Zwet et al., 1999). 
Resistance to fluoroquinolones: Fluoroquinolones inhibit the A subunit of the DNA gyrase, 
encoded by the gyrA gene. Mutations in the quinolone resistance-determining region of gyrA 
are found in H. pylori as well as in other bacteria (Tonkic et al., 2005; Bogaerts et al. 2006).  
Resistance to nitroimidazoles: 5-Nitroimidazoles have to be reduced in the cell to alter 
bacterial DNA. An important gene rdxA, an oxygen-insensitive nitroreductase. Mutations in 
rdxA can render the protein ineffective (Hoffman et al., 1996). However, it has not been 
possible to identify a clear panel of point mutations with the rdxA gene to explain the 
phenomenon of resistance (Mégraud, 2004). It is believed that other genes such as frxA may 
also be involved in the reduction process. MTZ-resistance reduces the efficacy of MTZ-
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containing regimens but does not make them completely ineffective. There is a discrepancy 
between in vitro MTZ-resistance and treatment outcome which may partially be explained by 
changes in oxygen pressure in the gastric environment as MTZ-resistant H. pylori isolates 
become MTZ-sensitive under low oxygen conditions in vitro (Gerrits et al., 2004).  
2.1.5.3 Prevention and control 
Eradication of the infection in individuals will improve symptoms including dyspepsia, 
gastritis and peptic ulcers, and may prevent gastric cancer. Rising antimicrobial resistance 
increases the need for a prevention strategy for the bacteria (Selgrad and Malfertheiner, 
2008). There have been extensive vaccine studies in mouse models, which have shown 
promising results (Hoffelner et al., 2008). Researchers are studying different adjuvants, 
antigens, and routes of immunization to ascertain the most appropriate system of immune 
protection, with most of the research only recently moving from animal to human trials 
(Kabir, 2007). An intramuscular vaccine against H. pylori infection is undergoing Phase I 
clinical trials and has shown an antibody response against the bacterium. Its clinical 
usefulness requires further study (Malfertheiner et al., 2008). 
A Japanese study  found that eating as little as 2.5 ounces of broccoli sprouts daily for two 
months reduces the number of colonies of H. pylori bacteria in the stomach by 40% in mice 
and humans (Lu et al., 2002). This treatment also seems to help by enhancing the protection 
of the gastric mucosa against H. pylori, but is relatively ineffective on related gastric cancers. 
The previous infection returned within two months after broccoli sprouts were removed from 
the diet, so an ongoing inclusion in the diet is best for continued protection from H. pylori 
(Yanaka, 2009). 
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2.2 STAPHTLOCOCCUS AUREUS 
2.2.1 HISTORY AND MORPHOLOGY 
Staphylococcus aureus was discovered in Aberdeen, Scotland in 1880 by the surgeon, Sir 
Alexander Ogston in pus from surgical abscesses (Dagan, 2000). S. aureus is a Gram-positive 
coccus, non-sporing, non-motile, usually non-capsulate, aerobic and normally facultative 
anaerobic cocci (1micrometer in diameter) arranged in grape-like clusters when viewed 
through a microscope (Zhu et al., 2008). The cell wall contains peptidoglycan and teichoic 
acid. The organisms are resistant to temperatures as high as 50°C, to high salt concentrations, 
and to drying. Colonies are usually large (6-8 mm in diameter), smooth, and translucent. The 
colonies of most strains are pigmented, ranging from cream-yellow to orange (Liu et al., 
2008).  
2.2.2 VIRULENCE FACTORS 
2.2.2.1 Toxins 
Depending on the strain, S. aureus is capable of secreting several toxins, which can be 
categorized into three groups. Many of these toxins are associated with specific diseases. 
Superantigens: (PTSAgs) have superantigen activities that induce toxic shock syndrome 
(TSS). This group includes the toxin TSST-1, which causes TSS associated with tampon use. 
The staphylococcal enterotoxins, which cause a form of food poisoning, are also included in 
this group (Cosgrove et al., 2009).  
Exfoliative toxins: EF toxins are implicated in the disease staphylococcal scalded-skin 
syndrome (SSSS). It also may occur as epidemics in hospital nurseries. The protease activity 
of the exfoliative toxins causes peeling of the skin observed with SSSS (Neely and Maley, 
2000).  
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Other toxins: Staphylococcal toxins that act on cell membranes include alpha-toxin, beta-
toxin, delta-toxin, and several bicomponent toxins. These toxins are associated with 
folliculitis, furuncle, carbuncle, endocarditis, thromblophlebitis and deep tissue abscess.  The 
bicomponent toxin Panton-Valentine leukocidin (PVL) is associated with severe necrotizing 
pneumonia in children. The genes encoding the components of PVL are encoded on a 
bacteriophage found in community-associated methicillin-resistant S. aureus (MRSA) strains 
(Whitt et al., 2002).  
2.2.2.2 Protein A 
Protein A is a protein that is anchored to staphylococcal peptidoglycan pentaglycine bridges 
by the transpeptidase Sortase A (Schneewind et al., 1995). Protein A is an IgG-binding 
protein that binds to the Fc region of an antibody. In fact, studies involving mutation of genes 
coding for Protein A resulted in a lowered virulence of S. aureus as measured by survival in 
blood, which has led to speculation that Protein A contributed virulence requires binding of 
antibody Fc regions(Dagan, 2000). Protein A in various recombinant forms has been used for 
decades to bind and purify a wide range of antibodies by immunoaffinity chromatography. 
Transpeptidases such as the sortases that are responsible for anchoring factors like Protein A 
to the staphylococcal peptidoglycan are being studied in hopes of developing new antibiotics 
to target MRSA infections (Zhu et al., 2008). 
2.2.2.3 Role of pigment in virulence 
Some strains of S. aureus are capable of producing staphyloxanthin - a carotenoid pigment 
that acts as a virulence factor. It has an antioxidant action that helps the microbe evade death 
by reactive oxygen species used by the host immune system. Staphyloxanthin is responsible 
for S. aureus characteristic golden colour (Cenci- Goga et al., 2003). When comparing a 
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normal strain of S. aureus with a strain modified to lack staphyloxanthin, the wildtype 
pigmented strain was more likely to survive incubation with an oxidizing chemical such as 
hydrogen peroxide than the mutant strain (Mackay, 2007).  
 Staphyloxanthin may be key to the ability of S. aureus to survive immune system attacks. 
Drugs designed to inhibit the bacterium's production of the staphyloxanthin may weaken it 
and renew its susceptibility to antibiotics. In fact, because of similarities in the pathways for 
biosynthesis of staphyloxanthin and human cholesterol, a drug developed in the context of 
cholesterol-lowering therapy was shown to block S. aureus pigmentation and disease 
progression in a mouse infection model (Dagan, 2000). 
2.2.4 LABORATORY DIAGNOSIS 
2.2.4.1 Culture  
Depending upon the type of infection present, an appropriate specimen is obtained 
accordingly and sent to the laboratory for definitive identification by using biochemical or 
enzyme-based tests. A Gram stain is first performed to guide the way, which should show 
typical gram-positive bacteria, cocci, in clusters (Dagan et al., 2000). Second, the isolate is 
cultured on mannitol salt agar, which is a selective medium with 7–9% NaCl that allows S. 
aureus to grow, producing yellow-colored colonies as a result of mannitol fermentation and 
subsequent drop in the medium's pH (Pericone et al., 2000); often with hemolysis when 
grown on blood agar plates (Lysenko et al., 2005). 
2.2.4.2 Biochemical tests 
S. aureus is catalase-positive (meaning that it can produce the enzyme catalase) and able to 
convert hydrogen peroxide (H2O2) to water and oxygen, which makes the catalase test useful 
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to distinguish staphylococci from enterococci and streptococci (Kaplan et al., 2004). A small 
percentage of S. aureus can be differentiated from most other staphylococci by the coagulase 
test: S. aureus is primarily coagulase-positive that causes clot formation, whereas most other 
Staphylococcus species are coagulase-negative (Grau et al., 2008). For staphylococcal food 
poisoning, phage typing can be performed to determine if the staphylococci is recovered from 
the food to determine the source of infection (Dagan, 2000). 
2.2.4.3 Rapid diagnosis  
Diagnostic microbiology laboratories and reference laboratories are key for identifying 
outbreaks and new strains of S. aureus. Recent genetic advances have enabled reliable and 
rapid techniques for the identification and characterization of clinical isolates of S. aureus in 
real-time. These tools support infection control strategies to limit bacterial spread and ensure 
the appropriate use of antibiotics. These techniques include real-time PCR and quantitative 
PCR and are increasingly being employed in clinical laboratories (Borchadt et al., 2003).  
2.2.5 TRANSMISSION, SOURCES OF INFECTION, TREATMENT AND 
RESISTANE MECHANISMS. 
Spread of S. aureus (including MRSA) is through human-to-human contact, although 
recently some veterinarians have discovered that the infection can be spread through pets, 
with environmental contamination thought to play a relatively unimportant part (Liu et al., 
2008). 
S. aureus colonizes mainly the nasal passages, but it may be found regularly in most other 
anatomical locales, including the skin, oral cavity and gastrointestinal tract. About 20% of the 
human population are long-term carriers of S. aureus (Chambers, 2001). 
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The treatment of choice for S. aureus infection is penicillin; but in most countries, penicillin-
resistance is extremely common and first-line therapy is most commonly a penicillinase-
resistant penicillin (for example, oxacillin or flucloxacillin). Combination therapy with 
gentamicin may be used to treat serious infections like endocarditis, but its use is 
controversial because of the high risk of damage to the kidneys. The duration of treatment 
depends on the site of infection and on severity (Neely and Maley, 2000).  
2.2.5.1 Resistance mechanisms to antibiotics. 
Alterations in target enzymes, membrane permeability, and efflux mechanisms cause drug 
resistance in methicillin-sensitive and methicillin-resistant Staphylococcus aureus (MRSA). 
A common mechanism of resistance for S. aureus is alterations in type II topoisomerases.
 
Subunits of topoisomerase IV are encoded by genes grlA and grlB. These genes are 
analogous to parC and parE, respectively (O`Donnell et al., 2000). Mutations in 
topoisomerase IV precede alterations in DNA gyrase when exposed to most 
fluoroquinolones.
 
Studies suggest that topoisomerase IV is the major target of quinolone 
activity against S. aureus (Heaton et al., 2000).  Moxifloxacin have equivalent activity 
against S. aureus. High MICs are found in S. aureus strains that have changes in both target 
enzymes. Combinations of topoisomerase mutations prevail in quinolone-resistant clinical 
isolates that are also methicillin resistant (Heaton et al., 2000). 
The efflux mechanism responsible for quinolone resistance in S. aureus is mediated by the 
production of the NorA protein. This cytoplasmic protein is an efflux transporter of 
quinolones and may be an inducible method of resistance. NorA-mediated resistance exists in 
isolates with and without accompanying topoisomerase mutations.
 
NorA appears to have 
greater affinity for pumping hydrophilic quinolones (norfloxacin, enoxacin) (O`Donnell et 
al., 2000). 
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2.2.6 PREVENTION  
Emphasis on basic hand washing techniques is effective in preventing the transmission of S. 
aureus (Bayer et al., 1998). No vaccine is generally available that stimulates active immunity 
against staphylococcal infections in humans. A vaccine based on fibronectin binding protein 
induces protective immunity against mastitis in cattle and might also be used as a vaccine in 
humans. However, vaccine therapies represent a new and innovative approach in broadening 
the available clinical tools against the global health problem of community and healthcare-
associated S. aureus bacterial infections (Cosgrove et al., 2009).  
Hyperimmune serum or monoclonal antibodies directed towards surface components (e.g., 
capsular polysaccharide or surface protein adhesions) could theoretically prevent bacterial 
adherence and promote phagocytosis by opsonization of bacterial cells. Also, human 
hyperimmune serum could be given to hospital patients before surgery as a form of passive 
immunization. When the precise molecular basis of the interactions between staphylococcal 
adhesins and host tissue receptors is known, it might be possible to design compounds that 
block the interactions and thus prevent bacterial colonization. These could be administered 
systemically or topically (Dagan et al., 2000).  
The pharmaceutical company, Nabi, has developed a trivalent staphylococcal polysaccharide 
conjugate vaccine called TriStaph. It contains the two main capsular types, 5 and 8, found in 
the outer coating of more than 80% of S. aureus strains, conjugated to nontoxic recombinant 
Pseudomonas exotoxin A (Zhu et al., 2008). To enhance the efficacy of this vaccine, a 
surface polysaccharide, 336, is added. S. aureus Type 336 accounts for approximately 20% of 
S. aureus infections that do not form a polysaccharide capsule in the human bloodstream. The 
336 conjugate vaccine, has been shown to be safe and generate antibodies in humans that are 
specific and mediate protection against 336-positive strains of S. aureus (Zhu et al., 2008). 
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Together, these polysaccharide conjugates can cover all clinically-significant serological 
types of S. aureus.  
2.3 AEROMONAS HYDROPHILA 
2.3.1 MORPHOLOGY 
Aeromonas hydrophila is a heterotrophic Gram-negative, non-spore-forming, rod-shaped, 
oxidase-positive, facultative anaerobic bacilli belonging to the family Aeromonadaceae and it 
is the only one of six Aeromonas species that is known to be pathogenic in humans (Villari et al., 
2003). It is usually from 0.3 to 1 micrometer in width, and 1 to 3 micrometers in length. 
Aeromonas hydrophila does not form endospores, and can grow in temperatures as low as 
four degrees celsius. These bacteria are motile by polar flagella (Havelaar et al., 1992; Janda 
and Abbott, 1998; Villari et al., 2003).  
2.3.2 PATHOGENESIS AND CLINICAL MANIFESTATIONS 
It was believed that the pathogenicity of Aeromonas species is mediated by a number of 
extracellular proteins such as aerolysin, lipase, chitinase, amylase, gelatinase, hemolysins and 
enterotoxins (Albert, 2000).  The type III secretion system (TTSS) mediated pathogenic 
mechanism has been proven to play a pivotal role in Aeromonas pathogenesis. The TTSS is 
specialized protein secretion machinery that export virulence factors delivered directly to host 
cells. These factors subvert normal host cell functions in ways that are beneficial to invading 
bacteria. In contrast to the general secretory pathway, type III secretion system is triggered 
when a pathogen comes in contact with host cells. ADP-ribosylation toxin is one of the 
effector molecules secreted by several pathogenic bacteria and translocated through TTSS 
and delivered into the host cytoplasm leads to interruption of NF-κB pathway, cytoskeletal 
damage and apoptosis. This toxin has been characterized in Aeromonas hydrophila (human 
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diarrhoeal isolate), Aeromonas salmonicida (fish pathogen) and Aeromonas jandaei GV17, a 
pathogenic strain which can cause disease both in human and fish (Chopra et al., 2000). 
2.3.2.1 Clinical manifestation 
One of the diseases it can cause in humans is gastroenteritis. This bacterium has been known 
to cause a generalized infection and spread throughout the body in persons with weak or 
defective immune systems, malignancies and other preexisting diseases. In such individuals, 
a generalized infection can be life-threatening. This bacterium is linked to two types of 
gastroenteritis. The first type is a disease similar to cholera, which causes rice-water diarrhea. 
The other is dysenteric gastroenteritis, which causes loose stools filled with blood and mucus. 
Dysenteric gastroenteritis is the most severe of the two types, and can last for multiple weeks 
(Sautour et al., 2003).The organism is also associated with cellulitis, an infection that causes 
inflammation in the skin tissue (Gavriel et al., 1998). It also causes diseases such as 
myonecrosis and eczema in people with compromised immune systems (Chauret et al., 
2001).  
2.3.3 LABORATORY DIAGNOSIS 
2.3.3.1 Culture 
Depending upon the type of infection present, an appropriate specimen is obtained 
accordingly and sent to the laboratory for definitive identification by using biochemical tests. 
A Gram stain is first performed, which should show typical rod shaped, gram-negative 
bacteria (Dagan et al., 2004).  A. hydrophila can easily grow on culture media e.g., nutrient or 
Muller- Hilton agar, the role of culture in diagnosis of the infection is limited mostly to 
research and epidemiologic considerations but does have a role in antibiotic susceptibility 
studies and studies of growth factors and metabolism (Perez-Perez, 2000). 
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2.3.3.2 Polymerase chain reaction 
PCR is a powerful tool that is used effectively in the identification and detection of A. 
hydrophila infection. PCR allows identification of the organism in small samples with few 
bacteria present and entails no special requirements in processing and transport. Moreover, 
PCR can be performed rapidly and it can be used to identify different strains for pathogenic 
and epidemiologic studies (Bravos and Gilman, 2000).  
2.3.4 TRANSMISSION, SOURCES OF INFECTION AND TREATMENT 
The common routes of infection suggested for Aeromonas are the ingestion of contaminated 
water or food or contact of the organism with a break in the skin (Schubert, 1991). No 
person-to-person transmission has been reported (Havelaar et al., 1992; Moyer et al., 1992; 
Hänninen and Siitonen, 1995; WHO, 2002; Borchardt et al., 2003). The growth of A. 
hydrophila is temperature dependent. Therefore, the risk of infection occur most during 
environmental changes, stressors, change in temperature; is highest in the summer months, 
when these microorganisms are multiplying more rapidly (Holmes and Nicolls, 1995).  
A. hydrophila  is a bacterium that is commonly found in freshwater environments and in 
brackish water ( lakes, rivers, marine waters, sewage effluents, and drinking waters)  (Allen 
et al., 1983; Nakano et al., 1990; Poffe and Op de Beeck, 1991; Payment et al., 1993; 
Ashbolt et al., 1995; Bernagozzi et al., 1995). They can survive in aerobic and anaerobic 
environments. 
 The organism can be eliminated using one percent sodium hypochlorite solution and two percent 
calcium hypochlorite solution. Antibiotic agents such as chloramphenicol, florenicol, 
tetracycline, sulfonamide, nitrofuran derivatives, and pyrodinecarboxylic acids are used to 
eliminate and control the infection (Chauret et al., 2001; El-Taweel and Shaban, 2001).  
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2.4 MEDICINAL PLANTS AND SOLVENTS EMPLOYED IN THE STUDY OF 
PLANT ANTIMICROBIALS.  
Medicinal plants are sources of alternative and complementary medicine. Ethnobotanical 
studies are often significant in revealing locally important plant species especially for the 
discovery of drugs. From its beginning, the documentation of traditional knowledge, 
especially on the medicinal uses of plants, has provided many important drugs of modern day 
(Adebolu, 2005). Traditional medicine still remains the main resource for a large majority of 
the people in Africa for treating health problems (Abebe and Hagos, 1991; Addis et al., 
2001). 
Medicinal plants signify a rich source from which antimicrobial agents may be obtained. 
Studies revealed that natural antimicrobials can act as resistant microbial inhibitors (Adebolu, 
2005). There is an increased need for the isolation and identification of new antimicrobials 
that are capable of inhibiting and treating a wide range of microorganisms including multi-
drug resistant strains. Plants have been documented to have these compounds that contribute 
to their antimicrobial activity including phytochemicals such as flavonoids, phenolics and 
propolis which are not fully characterized but posses antimicrobial activity against bacterial 
pathogens (Cushnie and Lamb, 2005). 
The type of solvent used may have an effect on the nature of the compounds extracted and 
the resulting bioactivity of the extract (Eloff, 1998b; Eloff et al., 2008). To ascertain the 
value of each extractant therefore, several parameters, including the rate of extraction, the 
quantity extracted, the diversity of compounds extracted, the diversity of inhibitory 
compounds extracted, the ease of subsequent handling of the extracts, toxicity of the solvent 
in the bioassay process and the potential health hazard of the extractants have to be evaluated. 
The efficiency of extraction has to be optimized to ensure that as many of the potentially 
active constituents as possible are extracted. A series of solvents of varying polarity (hexane, 
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carbon tetrachloride, di-isopropyl ether, ethyl ether, methylene dichloride, tetrahydrofuran, 
chloroform, acetone, ethanol, ethyl acetate, methanol, water or mixtures of different solvents) 
are used on the plant material (Eloff et al., 2008). In enormous reports, methanol or ethanol 
are used for alkaloid extraction; acetone for flavonoids and steroids, hexane, diethyl ether and 
chloroform for fat soluble oils, wax, lipids and esters; dichloromethane for terpenoids, ethyl 
acetate for esters, ethanol may also be used for sterols, polyphenols, tannins and water for the 
water soluble components like glycosides, polysaccharides, polypeptides and lectins, which 
are very effective against pathogens probably because of their ability to intercalate with DNA 
and/or cell membranes (Büssing, 1996). The crude extracts or mixtures of compound-rich 
residues are used for the initial screening of plants for anti-microbial activities. Thin Layer 
Chromatography (TLC), other chromatography separations and several solvent systems are 
used for the elution of many water and organic solvent soluble anti-microbial compounds 
(Eloff, 1998b; Eloff et al., 2008).  
 
2.4.1 Hydnora africana 
2.4.1.1 Description, Distribution and habitat. 
Hydnora africana is a parasitic plant of the genus Euphorbia. It has such an unusual physical 
appearance that one would never say it is a plant. It looks astonishingly similar to fungi and is 
only distinguishable from fungi when the flower has opened. Hydnora africana is specifically 
associated with species of Euphorbia, commonly E. mauretanica and E. tirucalli, found in 
the dry and semi-arid parts of the Succulent Karoo, Little Karoo, Eastern Cape Karoo, and the 
dry coastal thickets between the Eastern Cape and KwaZulu-Natal province of South Africa. 
It grows very close to its host plant but may not be seen in the drier parts of the year. It occurs 
in both winter and summer rainfall areas with the most common vegetation being the 
Succulent Karoo, and Eastern Cape Karoo. It is found from the western coastal areas of 
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Namibia, southwards to the Cape and then northwards throughout Swaziland, Botswana, 
KwaZulu-Natal and as far as Ethiopia (Asfaw et al., 1999). 
2.4.1.2 Uses and cultural aspects  
The fruit of Hydnora africana is said to be a traditional Khoi food, but there are no recorded 
details to confirm this. The fruit is delicious when baked and has a sweetish taste. Jackal food 
is used in a series of Cape dishes as recorded in the recipe book of Betsie Rood, Kos uit die 
veldkombuis (Rood, 1994). One of the recipes describes how the fruit pulp can be mixed with 
cream to make a delicious dessert. The fruit is extremely astringent and has been used for 
tanning and preserving fishing nets. Diarrhoea, dysentery, kidney and bladder complaints are 
all treated with infusions and decoctions of the plant. Infusions used as a face wash also treat 
acne (Van wyk and Gericke, 2000).  
Despite the documented uses of this plant in traditional medicine and the growing resistance 
of common bacterial pathogens, especially those under investigation in this study, we are not 
aware of any study that has investigated the antimicrobial potential of this plant against these 
pathogens. 
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CHAPTER THREE 
MATERIALS AND METHODS 
3.1 Bacterial strains 
The following standard strains of bacteria Aeromonas hydrophila ATCC 35654, 
Staphylococcus aureus NCT 6571, Helicobacter pylori ATCC 43526 and local clinical strain 
of Helicobacter pylori PE 252C isolated in our laboratory (Tanih et al., 2010) were used. 
Cultures of confirmed organisms were maintained on nutrient agar slants at 4°C 
(Cheesbrough, 1982; Cowan and Steel, 2004). H. pylori was suspended in 20% glycerol and 
stored at -80°C. 
 3.2 Preparation of plants extracts 
H. africana was selected based on ethnobotanical information and preliminary data obtained 
in our laboratory. It was identified in collaboration with botanists of the University of Venda, 
where voucher specimens have been deposited. 
The method described by Ndip et al. (2008) to prepare extracts was employed with 
modifications. The plant was harvested, air dried for 2 weeks and ground to fine powder 
using a blender (ATO MSE mix, 702732, England). Organic solvents including methanol, 
ethanol, acetone, ethyl acetate (100%) and water were used for extraction. The dried plant 
material, 2.5-2.8 kg, was macerated in five fold excess of the solvent in extraction pots such 
that the level of the solvents was above that of the plant material. The slurry was put in a 
shaker incubator (Edison, N.J., USA) regulated at room temperature (RT) for 48 hours then 
centrifuged at 300 rpm for 5 mins (Model TJ-6 Beckman, USA) and filtered using filter 
papers of pore size 60
Å
.The process was repeated twice for a total of three extractions. The 
combined extracts was concentrated in a rotavapor (BUCHI R461, Switzerland) and 
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transferred to appropriately labelled vials and allowed to stand at room temperature to permit 
evaporation of residual solvents. A 3 gram sample of each plant extract was used for the 
preliminary bioassay, and 3 g kept in the extract bank for subsequent use. Stock solutions 
were prepared by dissolving the extracts in 10% Dimethyl Sulphoxide (DMSO). 
3.3 Antibacterial susceptibility test 
The agar well diffusion technique was employed as previously described by Dastouri et al. 
(2008). For  H. pylori, Columbia base agar was prepared following the manufacturer’s 
instructions, supplemented with 7% defibrinated horse blood and skirrow’s antibiotics while 
for  A. Hydrophila and S. aureus, Muller-Hilton agar was prepared following the 
manufacturer`s instructions. A 0.5 McFarland standard was prepared by the method of 
Koneman et al. (1992), and 5mL put into a sterile test tube. An inoculum of each 
microorganism was prepared from subculture of bacterial suspension. With a sterile wire 
loop, four to five colonies of the same morphological type were picked and emulsified in 
0.9% physiological saline. The turbidity of the suspension was adjusted to correspond to 0.5 
MacFarland standard. An inoculum with the required turbidity was estimated to contain 10
8 
colony forming unit and used to evenly inoculate specific agar plates depending on the 
microorganisms. Five wells were cut in each agar plate with a cooled, flamed cork borer of 
6mm diameter, and the agar plugs removed with a sterile needle. About 100µL of the 
different concentrations (200, 100, 50 mg/mL) of the extract were put separately into each 
well, in each plate. Ciprofloxacin (0.0125mg/mL) was used as positive control.  The plates 
were incubated at 37ºC for 24 hours for A. hydrophila and S. aureus and 3-5 days for H. 
pylori under microaerobic conditions and the diameter of the zone of inhibition measured and 
recorded in millimeters. The experiment was repeated 2x for each strain. 
 
34 
 
3.4 Determination of minimum inhibitory concentration (MIC50) 
 MIC50 was carried out as described by (Banfi et al., 2003, Njume et al., 2010) with 
modifications. The microdilution test was performed in 96-well plates. Two-fold dilutions of 
the most potent extracts and antibiotic (ciprofloxacin) were prepared in the test wells in 
complete Brian Heart Infusion (BHI) broth, the final extracts and antibiotic concentrations  
ranged from 0.0024 –5mg/mL. Twenty microlitres of each bacterial suspension was added to 
180 μL of extract -containing culture medium. Control wells were prepared with culture 
medium and bacterial suspension only. Also included was culture medium and extract only at 
different concentrations. An automatic ELISA micro plate reader (Model 680, Bio-Rad, 
Japan) adjusted to 620nm was used to measure the absorbance of the plates before and after 
24 hours incubation. The absorbencies were compared to detect an increase or decrease in 
bacterial growth. The lowest concentration of the test extract resulting in inhibition of 50% of 
bacterial growth was recorded as the MIC.  
3.5 Determination of minimum bactericidal concentration (MBC) 
To determine the MBC, 0.2mL of the contents of the MIC was serially diluted tenfold in 
0.9% physiological saline (Ndip et al., 2007). A loop full was taken from each tube and 
inoculated onto BHI agar plates. The MBC was recorded as the lowest concentration of the 
extract that gave complete inhibition of colony formation of the test bacteria at the latter 
cultivation. 
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3.6 Phytochemical screening of the extracts 
A small portion of the dry extract was subjected to the phytochemical test using previously 
established methods (Akinpelu et al., 2008) to test for alkaloids, tannins, flavonoids, steroids 
and saponins. 
3.6.1 Test for alkaloids 
Exactly 0.5 g of the plant extract was dissolved in 5 mL of 1% HCl on steam bath. A 
millilitre of the filtrate was treated with drops of Dragendorff’s reagent. Turbidity or 
precipitation was taken as indicative of the presence of alkaloids. 
3.6.2 Test for tannins 
About 1 g of the extract was dissolved in 20 mL of distilled water and filtered. Two to three 
drops of 10%  FeCl3 were added to 2 mL of the filtrate. The production of a blackish-blue or 
blackish-green colouration was indicative of tannins. To another 2 mL of the filtrate was 
added 1 mL of bromine water. A precipitate was taken as positive for tannins. 
3.6.3 Test for flavonoids 
A 0.2 g of the extract was dissolved in 2 mL of methanol and heated. A chip of magnesium 
metal was added to the mixture followed by the addition of a few drops of concentrated HCl. 
The occurrence of a red or orange colouration was indication of the flavonoids. 
3.6.4 Test for saponins 
Two grams of the extract was boiled in 20mL of distilled water in a water bath and filtered 
(Acrodisc syringe filter pall, USA). Aprroximately 10mL of the filtrate was mixed with 5mL 
of distilled water and shaken vigorously for a stable persistent froth. The frosting was mixed 
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with 3 drops of olive oil and shaken vigorously, then observed for the formation of an 
emulsion 
3.6.5 Test for steroids 
About 0.5 g of the extract was dissolved in 3 mL of CHCl3 and filtered. Concentrated H2SO4 
was added to the filtrate to form a lower layer. A reddish brown colour was taken as positive 
for steroid ring. 
3.7 Statistical analysis 
Analysis was performed using the SPSS Version 17.0 (Illinois USA, 2009). The one way 
ANOVA test was used to determine if there was any statistically significant difference in the 
diameter of zones  of inhibition  of the different solvents extract of H. africana ; the MIC50 of 
the extracts and the control antibiotic (ciproxacillin). P-values <0.05 were considered 
significant.  
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CHAPTER FOUR  
RESULTS 
4.1 Extract yield 
Different solvents including ethyl acetate, acetone, ethanol, methanol and water were used for 
extraction because the type of solvent used may have an effect on the nature of the 
compounds extracted, the quantity extracted and the resulting bioactivity of the extract. Water 
extracted the highest quantity followed by methanol, ethanol, acetone and ethyl acetate (11.2, 
9.9, 5.6, 3 and1.5g) respectively (fig 1). 
 
Fig 1: Quantity (grams) of H.africana flower extracted with different solvents.  X-axis shows 
the different solvents used for extraction and Y-axis shows quantity extracted in grams. 
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4.2 Antimicrobial Susceptibility testing  
The plant extracts showed in vitro activity against all the bacterial pathogens used (S. aureus, 
A. hydrophila, H. pylori 43526 and clinical isolate of H. pylori P.E 252C) with the exception 
of water extracts. The mean zone diameter of inhibition ranged from 0mm to 22mm (Table 
1).  Acetone, methanol and ethyl acetate were the most active extracts against S. aureus, A. 
hydrophila with mean zone diameter of inhibition ranging from 13-22mm, while for H. 
pylori, methanol and ethyl acetate extracts showed activity with mean zone diameter ranging 
from 14-21mm. The most active crude extracts (methanol and ethyl acetate) against all test 
microorganisms were statistically significant (P< 0.05) compared to all other extracts. DMSO 
used as negative control, showed no activity. Ciprofloxacilin (0.0125mg/mL) was used as a 
positive control, with mean zone diameter ranging from 14-17mm. An inhibition zone of ≥ 
6mm was chosen as representative of bacterial susceptibility to the extracts. The breakpoint 
of ciprofloxacin (0.05mg/mL) is 21mm (CLSI, 2008). 
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Table 1:  Antibacterial activity of extracts of H.africana against selected bacterial pathogens 
  Zone diameter at  different concentration (mm)*         
 Methan
ol 
                              water                      Acetone  
mg/mL                                
     Ethyl acetate       Ethanol             Cipro Ciproxacillin 
 SBP                200        100 50             200     100    
  
50 200 
 
100 50 200 100 50 200 100 50          0.025 0.0125 
S.a   17±2.1 21±2.1 22±2.1      0 
 
0 0 20±0.7 
 
19±1.4 22±3.5 16±0.7 18±0.7 19±0.7 14±1.4 16±1.4 17±1.4     17±0.7 17±0.7 
A.h   17±0.7 16±0.7 15±1.4       0 
 
0 0 17±2.1 
 
17±1.4 18±1.4 14±1.4 13±1.4 15±0 13±0.7 16±1.4 14±0.7     17±1.4 17±1.4 
H.p1   20±0.7 16±1.4 15±1.4       0 0 0 0 
 
0 0 15±2.8 17±1.4 14±1.4 0 0 0              14±1.4 14±1.4 
H.p 2   17±2.1 21±2.1 18±0.7       0 
 
0 0 0 
 
0 0 16±0.7 19±1.4 17±0.7 0 0 0              15±0.7 15±0.7 
SBP, selected bacterial pathogens; S.a, S.aureus; A.h, A.hydrophila; H.P1, H.pylori 43526; H.p 2, H.pylori PE 252C; Cipro, ciprofloxacin;        
*, experiment was repeated twice and zone of inhibition recorded as mean zone diameter ±SD. Sensitivity zone ≥ 6mm  
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4.3 Minimum inhibitory concentration (MIC) and minimum bactericidal concentration         
(MBC) determination   
The active extracts were further assayed to determine their MIC50 and MBC against the 
bacterial pathogens. Although only methanol and ethyl acetate extracts showed activity 
against H. pylori; methanol, acetone, ethanol and ethyl acetate extracts were active against 
S.aureus and A. hydrophila. Subsequently methanol and ethyl acetate extracts were used for 
the determination of MIC50 and MBC for H. pylori (ATCC 43526 and PE 252C) and 
methanol, acetone, ethanol and ethyl acetate extracts were used to determine MIC50 and MBC 
for S.aureus and A. hydrophila. The MIC50 and MBC ranged from 0.078 – 2.5 mg/mL and 
0.78 – 25mg/mL respectively for all studied microorganisms (fig 2-5), (Table 2). MIC50 and 
MBC of ciprofloxacin ranged from 0.00976 – 0.078mg/mL and 0.098– 0.78mg/mL 
respectively (fig 6), (Table 2). This drug served as the positive control.  
The MIC50 was 0.078mg/mL, 0.15625mg/mL, 0.15625mg/mL and 0.625mg/mL for ethyl 
acetate, acetone, ethanol and methanol extracts against S. aureus respectively (fig 2). 
Furthermore, the MIC50 of A. hydrophila was 0.078mg/mL, 0.15625mg/mL and 
0.3125mg/mL for ethyl acetate, acetone and methanol extracts in that order; ethanol showed 
no activity at MIC50 (fig 3). For ethyl acetate and methanol extracts, the MIC50 was 
1.25mg/mL, 2.5mg/mL against H. pylori 43526 respectively (fig 4). Finally, the MIC50 was 
observed to be 2.5mg/mL for the ethyl acetate extract against H. pylori PE 252C; however 
the methanol extract showed no inhibition at MIC50 against H. pylori PE 252C (fig 5). The 
MIC50 of the antibiotic ciprofloxacin was 0.00976mg/mL, 0.00976mg/mL, 0.078mg/mL, 
0.078mg/mL; while the MBC were 0.098mg/mL, 0.098mg/mL, 0.78mg/mL and 0.78mg/mL 
for S. aureus,  A. hydrophila, H. pylori 43526 and  H. pylori PE 252C respectively (fig 6), 
(Table 2).       
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 Gram positive bacteria (S  aureus) was most susceptible to H. africana compared to the 
Gram negative bacteria (A. hydrophila and H. pylori). However, there was no statistically 
significant difference (P>0.05) between the MIC50 and MBC of different solvents against 
Gram negative and Gram positive organisms. Also, there was no statistically significant 
difference in activity between the extracts (methanol, acetone, ethanol, ethyl acetate) and the 
control antibiotic (ciprofloxacin). 
 
  
Fig 2: MIC50 of different solvent extracts against S. aureus.  X-axis shows concentration of 
extracts and Y-axis viability of S. aureus. neg, broth and isolate only; 0.0024mg/mL- 
5mg/mL, different concentration of crude extracts of H. africana; A, acetone; M, methanol; 
EA, ethyl acetate; E, ethanol.  
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Fig 3: MIC50 of different solvent extracts against A. hydrophila.  X-axis shows concentration 
of extracts and Y-axis viability of A. hydrophila. neg, broth and isolate only; 0.0024mg/mL- 
5mg/mL, different concentration of crude extracts of H. africana. A, acetone; M, methanol; 
EA, ethyl acetate; E, ethanol. 
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Fig 4: MIC50 of different solvent extracts against H. pylori 43526 (CTRL strain).  X-axis 
shows concentration of extracts and Y-axis viability of H. pylori 43526. neg, broth and 
isolate only; 0.0024mg/mL- 5mg/mL, different concentration of crude extracts of H. 
africana. A, acetone; M, methanol; EA, ethyl acetate; E, ethanol. 
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Fig 5: MIC50 of different solvent extracts against H. pylori PE 252C.  X-axis shows 
concentration of extracts and Y-axis viability of H. pylori. neg, broth and isolate only; 
0.0024mg/mL- 5mg/mL, different concentration of crude extracts of H. africana. A, acetone; 
M, methanol; EA, ethyl acetate;  E, ethanol. 
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Fig 6: MIC50 of antibiotic (ciprofloxacin) against selected bacterial pathogens.  X-axis shows 
concentration of antibiotic and Y-axis viability of H. pylori. neg, broth and isolate only; 
0.0024mg/mL- 5mg/mL, different concentration of ciproxacillin. 
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Table 2: MBC (mg/mL) of different solvent extracts of H. africana and antibiotic against    
selecte selected bacterial pathogens                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 
SBP 
 Extracts/ Antibiotic (mg/mL) 
Methanol Acetone Ethanol Ethyl acetate Ciprofloxacini 
S.aureus 6.25 1.56 1.56 0.78 0.098 
A.hydrophila 3.125 1.56 _ 0.78 0.098 
H.pylori43526 25 ND ND 12.5 0.78 
H.pylori252C _ ND ND _ 0.078 
SBP, selected bacterial pathogens; –, MBC values not within susceptible range; ND, not 
determined. 
 
4.5 Phytochemical analysis 
Phytochemical analysis of four extracts (methanol, acetone, ethanol and ethyl acetate) of H. 
africana is summarized in Table 3. The results revealed the presence of the following 
secondary metabolites: alkaloids, saponins, tannins, steroids and flavoinds, based on colour, 
heamolysis, turbidity, layers, emulsification and precipitation following the reactions. 
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Table 3: Phytochemical constituents of different solvent extracts of H.africana 
 
Phytochemicals 
 Solvent extracts   
Methanol Acetone Ethanol Ethyl acetate  
Alkaloids +++ ++ +++ ++  
Saponins +++ ++ ++ +++  
Tannins +++ +++ +++ +++  
Flavonoids +++ +++ +++ +++  
Steroids +++ +++ +++ +++  
+++, Present in large quantity;  ++, Present in moderate quantity. 
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CHAPTER FIVE 
DISCUSSION, CONCLUSION AND RECOMMENDATIONS. 
5.1 Discussion  
The phytoconstituents of various plants have longed been known and their antimicrobial 
properties have been widely reported (Nostro et al., 2000; Roy et al., 2006). The 
antimicrobial activities of plant extracts have been linked to the presence of some bioactive 
compounds. These secondary metabolites also serve to protect the plants themselves against 
bacterial, fungal and viral infections (De and Ijeoma, 2002; El-Mahmood and Amey, 2007). 
These bioactive compounds are known to work synergistically to produce various effects on 
the human and animal subjects (Amagase, 2006). However, most reports on Hydnora 
africana have focused mainly on the morphology of the plant because it has a bizarre shape, 
while information on its activity against hospital based pathogens is scanty (Bolin et al., 
2009). 
The extraction of active compounds from plant material depends on the type of solvent used 
in the extraction process (Parekh et al., 2005; Majhenic et al., 2007). In this study, it was 
observed that plant extractions with organic solvents provided stronger antibacterial activity 
than extraction with water. This study confirms the results of previous studies, which 
reported that water is not a suitable solvent for extraction of antibacterial compounds from 
medicinal plants compared to organic solvents, such as methanol, acetone and ethyl acetate 
(Karaman et al, 2003; Moniharapon and Hashinaga, 2004; Parekh et al, 2005; Majhenic et al, 
2007). This finding is also correlated with the medicinal preparations that use rum and liquor 
to extract the active plant components (Jhon et al., 2006). Extract yields of water, methanol, 
49 
 
ethanol, acetone and ethyl acetate were 11.2g, 9.9g, 5.6g, 3g and 1.5g respectively after one 
extraction.  
H. africana exhibited a stronger antibacterial activity against H. pylori than previously 
reported plants including Eryngium foetidium, Euphorbia hirta and Tapienachilus ananassae 
(Ndip et al., 2007). Their mean zone diameter of inhibition ranged from 0–18mm (Ndip et 
al., 2008) while in the present study the mean zone diameter ranged from 0–21mm (Table 1). 
In line with the findings of this study, another study had demonstrated very potent 
antibacterial activity of Hydnora abyssinica. In their study, Saadabi and Ayoub et al. (2009) 
screened crude extracts of the family Hydnoracea (H. africana also belong in this family), 
and reported potent antibacterial activity against common pathogenic gram-negative and 
positive bacteria including Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis and 
Staphylococcus aureus.  
In the present study MIC50 and MBC recorded for H. africana against all studied 
microorganisms ranged from 0.078–2.5mg/mL and 0.78–25mg/mL respectively. However, 
the methanol extract showed no inhibition at MIC50 against H.pylori PE 252C. The MIC 
results confirm earlier findings by Nariman et al. (2004) who documented MIC ranges of 
0.0037–2 mg/mL. Also, MIC values of 0.0625–0.5 mg/mL have been documented for East 
African medicinal plants against similar bacteria pathogens (Fabry et al., 1996).  
Moreover in line with our finding, another study had demonstrated very potent antibacterial 
activity of Afzelia Africana. In their study, Akinpelu et al. (2008) screened crude extracts of 
A. africana commonly used to treat bacterial infections. They tested this plant on common 
pathogenic gram-negative and positive bacteria including Staphylococcus aureus amongst 
other microorganisms. Their lowest MIC recorded was 1.56 mg/mL and the lowest MBC was 
3.13 mg/mL. MIC50 and MBC of the antibiotic (ciprofloxacin) ranged from 0.00976-
0.078mg/mL; 0.098– 0.78mg/mL for all tested bacterial pathogens respectively and was not 
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statistically significant in activity (P>0.05) compared to the extracts. Such results provide 
evidence that some medicinal plants might be potential sources of new antibacterial agents 
even against some resistant strains. 
 Gram positive bacteria (S. aureus) was most susceptible to H.africana compared to the Gram 
negative bacteria (A. hydrophila and H. pylori). Most plants extracts are most active against 
Gram positive bacteria; this has been attributed to the fact that the cell wall of Gram positive 
bacteria is easier to penetrate than the Gram negative bacteria which contains outer 
membrane with a lipopolysacharide layer which is impermeable to certain antibiotics and 
antibacterial compounds (Nikaido, 1996; Fennell et al., 2004).  
Phytochemical analysis of the extracts of H. africana revealed the presence of alkaloids, 
saponins, tannins, flavonoids and steroids (Table 3). These phytochemical compounds are 
known to be biologically active and thus aid the antimicrobial activities of plants. Alkaloids 
was one of the phytochemical compounds identified in this study. They have been allied with 
medicinal uses for centuries. Most common biological properties of alkaloids are their 
toxicity against cells of foreign organisms, antiinflammatory, anti-asthmatic, and anti- 
anaphylactic properties (Gopalakrishnan et al., 1979; Ganguly and Sainis, 2001; Staerk et al., 
2002) and may be responsible for the observed activity.  
The presence of flavonoids in crude extract   of H. africana is important since they have been 
reported to exhibit  antimicrobial, anti-inflammatory, anti-angionic, analgesic, anti-allergic, 
cytostatic, antioxidant, antitrypanosomal and antileishmanial properties (Hodek et al., 2002). 
Flavonoids exhibit a wide range of biological activities such as the ability of scavenging 
hydroxyl radicals, superoxide anion radicals and lipid peroxyradicals. These radicals are 
important for prevention of diseases associated with oxidative damage of membrane, proteins 
and DNA (Ferguson, 2001). Flavonoids in human diet may reduce the risk of various cancers, 
51 
 
coronary heart diseases as well as preventing menopausal symptoms (Xu et al., 2000; Hodek 
et al., 2002; Tasdemir et al., 2006).  
 Saponins and tannins were also reported in this study. Saponins are responsible for numerous 
pharmacological properties and are known to produce inhibitory effects on inflammation 
(Just et al., 1998; Estrada et al., 2000). Tannins exert antimicrobial activities by iron 
deprivation, hydrogen bonding or specific interactions with vital proteins such as enzymes in 
microbial cells (Njume et al., 2009). Herbs that have tannins are astringent in nature and are 
used for treating intestinal disorders such as diarrhoea and dysentery (Dharmananda, 2003). 
Motar et al. (1985) revealed the importance of tannins for the treatment of inflamed or 
ulcerated tissues. Tannins were observed to have remarkable activity in cancer prevention (Li 
et al., 2003), this is important noting that H. africana could have potentials as a source of 
important bioactive molecules for the treatment of cancer (Trease and Evans, 1983). Lastly 
steroidal compounds were also present in the crude extracts of H. africana; they have drawn 
much interest in pharmacy due to their relationship with such compounds as sex hormones 
(Okwu, 2001).  
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5.2 Conclusion 
From the results obtained, the following conclusions can be drawn: 
1. The study demonstrated the in vitro activities of the crude extracts of H.africana and 
provides preliminary evidence for the use of this plant in traditional medicine.  
2. The MIC50 and MBC of the crude extracts ranged from 0.078–2.5mg/mL, 0.78-
25mg/mL respectively. 
3. Alkaloids, saponnins, tannins, flavonoids and steroids were identified in the extracts 
of the plant. 
5.3 Recommendations 
1.  Bioassay-guided fractionation should be conducted to determine the active 
compounds in H. africana. 
2. The toxicity of the compounds should be determined. 
3. In vivo animal model studies should be conducted to ascertain their healing potential. 
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APPENDICES 
Appendix 1 
Representative photographs of sites of infection and plant under study 
 
Fig 1: H.africana (flower) 
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Fig 2: Stomach ulcers caused by H.pylori 
 
Fig 3: Pneumonia caused by Staphylococcus aureus 
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Fig 4: Wound caused by Staphylococcus aureus 
 
Fig 5: Eczema caused by Aeromonas hydrophila 
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Appendix 2 
Media used in this study and preparation. 
Preparation of culture media 
The culture media was composed of Columbia Blood Agar (CBA), skirrow`s antibiotics and 
7% horse blood for H. pylori. CBA was prepared using the manufacturer`s instructions which 
indicated 39g/L of the agar for H. pylori; while for S. aureus and A. hydrophila, Muller- 
Hilton agar was prepared following manufacturer`s instructions which indicated 38g/L. The 
mixtures were boiled to dissolve and sterilized in an autoclave at 121°C for 15 minutes. It 
was allowed to cool then poured in plates.   
Preparation of Brain Heart Infusion agar 
It was prepared following the manufacturer`s instructions which indicated 47g/L of the broth. 
The mixture was boiled to dissolve and sterilized in an autoclave at 121°C for 15min. It was 
allowed to cool (50°C), after which 2ml of skirrow`s antibiotics and 35ml of 7% horse blood 
were added. 
 
 
 
 
 
 
 
81 
 
Appendix 3 
Statistical observations 
Antibacterial activity of different solvents extract of H.africana against tested bacterial 
strains at 200mg/ml 
 
Multiple Comparisons 
Zd 
Tukey HSD 
(I) ext (J) ext Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 
d
i
m
e
n
s
i
o
n
3 
2 8.2500 4.1370 .315 -4.525 21.025 
3 10.6250 4.1370 .127 -2.150 23.400 
4 2.2500 4.1370 .981 -10.525 15.025 
5 17.2500
*
 4.1370 .006 4.475 30.025 
2 
d
i
m
e
n
s
i
o
n
3 
1 -8.2500 4.1370 .315 -21.025 4.525 
3 2.3750 4.1370 .977 -10.400 15.150 
4 -6.0000 4.1370 .607 -18.775 6.775 
5 9.0000 4.1370 .241 -3.775 21.775 
3 
d
i
m
1 -10.6250 4.1370 .127 -23.400 2.150 
2 -2.3750 4.1370 .977 -15.150 10.400 
4 -8.3750 4.1370 .301 -21.150 4.400 
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e
n
s
i
o
n
3 
5 6.6250 4.1370 .519 -6.150 19.400 
4 
d
i
m
e
n
s
i
o
n
3 
1 -2.2500 4.1370 .981 -15.025 10.525 
2 6.0000 4.1370 .607 -6.775 18.775 
3 8.3750 4.1370 .301 -4.400 21.150 
5 15.0000
*
 4.1370 .018 2.225 27.775 
5 
d
i
m
e
n
s
i
o
n
3 
1 -17.2500
*
 4.1370 .006 -30.025 -4.475 
2 -9.0000 4.1370 .241 -21.775 3.775 
3 -6.6250 4.1370 .519 -19.400 6.150 
4 -15.0000
*
 4.1370 .018 -27.775 -2.225 
*. The mean difference is significant at the 0.05 level. 
 
1=Methanol, 2=Acetone, 3=Ethanol, 4=Ethyl acetate, 5=water 
 
Antibacterial activity of different solvents extract of H.africana against tested bacterial 
strains at 100mg/ml 
Multiple Comparisons 
Zd 
Tukey HSD 
(I) ext (J) ext Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 
d
i
2 9.5000 4.3853 .244 -4.042 23.042 
3 11.2500 4.3853 .128 -2.292 24.792 
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m
e
n
s
i
o
n
3 
4 1.8750 4.3853 .992 -11.667 15.417 
5 18.5000
*
 4.3853 .006 4.958 32.042 
2 
d
i
m
e
n
s
i
o
n
3 
1 -9.5000 4.3853 .244 -23.042 4.042 
3 1.7500 4.3853 .994 -11.792 15.292 
4 -7.6250 4.3853 .442 -21.167 5.917 
5 9.0000 4.3853 .290 -4.542 22.542 
3 
d
i
m
e
n
s
i
o
n
3 
1 -11.2500 4.3853 .128 -24.792 2.292 
2 -1.7500 4.3853 .994 -15.292 11.792 
4 -9.3750 4.3853 .255 -22.917 4.167 
5 7.2500 4.3853 .489 -6.292 20.792 
4 
d
i
m
e
n
s
i
o
n
3 
1 -1.8750 4.3853 .992 -15.417 11.667 
2 7.6250 4.3853 .442 -5.917 21.167 
3 9.3750 4.3853 .255 -4.167 22.917 
5 16.6250
*
 4.3853 .013 3.083 30.167 
5 
d
i
m
1 -18.5000
*
 4.3853 .006 -32.042 -4.958 
2 -9.0000 4.3853 .290 -22.542 4.542 
3 -7.2500 4.3853 .489 -20.792 6.292 
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e
n
s
i
o
n
3 
4 -16.6250
*
 4.3853 .013 -30.167 -3.083 
*. The mean difference is significant at the 0.05 level. 1=Methanol, 2=Acetone, 3=Ethanol, 
4=Ethyl acetate, 5=water 
 
 
Antibacterial activity of different solvents extract of H.africana against tested bacterial 
strains at 50mg/ml 
 
 
Multiple Comparisons 
Zd 
Tukey HSD 
(I) ext (J) ext Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 
d
i
m
e
n
s
i
o
n
3 
2 7.3750 4.7445 .546 -7.276 22.026 
3 9.6250 4.7445 .300 -5.026 24.276 
4 1.1250 4.7445 .999 -13.526 15.776 
5 17.2500
*
 4.7445 .018 2.599 31.901 
2 
d
i
m
e
n
s
i
o
n
3 
1 -7.3750 4.7445 .546 -22.026 7.276 
3 2.2500 4.7445 .989 -12.401 16.901 
4 -6.2500 4.7445 .685 -20.901 8.401 
5 9.8750 4.7445 .278 -4.776 24.526 
3 
d
1 -9.6250 4.7445 .300 -24.276 5.026 
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i
m
e
n
s
i
o
n
3 
2 -2.2500 4.7445 .989 -16.901 12.401 
4 -8.5000 4.7445 .413 -23.151 6.151 
5 7.6250 4.7445 .515 -7.026 22.276 
4 
d
i
m
e
n
s
i
o
n
3 
1 -1.1250 4.7445 .999 -15.776 13.526 
2 6.2500 4.7445 .685 -8.401 20.901 
3 8.5000 4.7445 .413 -6.151 23.151 
5 16.1250
*
 4.7445 .028 1.474 30.776 
5 
d
i
m
e
n
s
i
o
n
3 
1 -17.2500
*
 4.7445 .018 -31.901 -2.599 
2 -9.8750 4.7445 .278 -24.526 4.776 
3 -7.6250 4.7445 .515 -22.276 7.026 
4 -16.1250
*
 4.7445 .028 -30.776 -1.474 
*. The mean difference is significant at the 0.05 level. 1=Methanol, 2=Acetone, 3=Ethanol, 
4=Ethyl acetate, 5=water 
 
 
MIC50 of different solvent extracts 
 
Multiple Comparisons 
Mic 
Tukey HSD 
(I) ext (J) ext Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 
d
i
2 5.0781250000 2.9719521691 .361 -3.745307128 13.901557128 
3 4.9218750000 2.9719521691 .386 -3.901557128 13.745307128 
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m
e
n
s
i
o
n
3 
4 3.8086250000 2.9719521691 .591 -5.014807128 12.632057128 
2 
d
i
m
e
n
s
i
o
n
3 
1 -5.0781250000 2.9719521691 .361 -13.901557128 3.745307128 
3 -.1562500000 2.9719521691 1.000 -8.979682128 8.667182128 
4 -1.2695000000 2.9719521691 .973 -10.092932128 7.553932128 
3 
d
i
m
e
n
s
i
o
n
3 
1 -4.9218750000 2.9719521691 .386 -13.745307128 3.901557128 
2 .1562500000 2.9719521691 1.000 -8.667182128 8.979682128 
4 -1.1132500000 2.9719521691 .981 -9.936682128 7.710182128 
4 
d
i
m
e
n
s
i
o
n
3 
1 -3.8086250000 2.9719521691 .591 -12.632057128 5.014807128 
2 1.2695000000 2.9719521691 .973 -7.553932128 10.092932128 
3 1.1132500000 2.9719521691 .981 -7.710182128 9.936682128 
 
1=Methanol, 2=Acetone, 3=Ethanol, 4=Ethyl acetate 
 
MBC of different solvent extracts 
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Multiple Comparisons 
mbc 
Tukey HSD 
(I) ext (J) ext Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1 
d
i
m
e
n
s
i
o
n
3 
2 4.3433614000 3.0918916392 .520 -4.836159155 13.522881955 
3 4.3827490000 3.0918916392 .513 -4.796771555 13.562269555 
4 4.3827474250 3.0918916392 .513 -4.796773130 13.562267980 
2 
d
i
m
e
n
s
i
o
n
3 
1 -4.3433614000 3.0918916392 .520 -13.522881955 4.836159155 
3 .0393876000 3.0918916392 1.000 -9.140132955 9.218908155 
4 .0393860250 3.0918916392 1.000 -9.140134530 9.218906580 
3 
d
i
m
e
n
s
i
o
n
3 
1 -4.3827490000 3.0918916392 .513 -13.562269555 4.796771555 
2 -.0393876000 3.0918916392 1.000 -9.218908155 9.140132955 
4 -.0000015750 3.0918916392 1.000 -9.179522130 9.179518980 
4 
d
i
1 -4.3827474250 3.0918916392 .513 -13.562267980 4.796773130 
2 -.0393860250 3.0918916392 1.000 -9.218906580 9.140134530 
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m
e
n
s
i
o
n
3 
3 .0000015750 3.0918916392 1.000 -9.179518980 9.179522130 
 
1=Methanol, 2=Acetone, 3=Ethanol, 4= Ethyl acetate 
 
 
Multiple Comparisons FOR MICS of the extracts and antibiotics 
MIC 
Tukey HSD 
(I) EXTS (J) EXTS Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
dimensio
n2 
1 
dimension3 
2 .96354167 .60662512 .527 -.9266680 2.8537513 
3 .80729167 .60662512 .678 -1.0829180 2.6975013 
4 -.30595833 .60662512 .986 -2.1961680 1.5842513 
5 .95541667 .60662512 .535 -.9347930 2.8456263 
2 
dimension3 
1 -.96354167 .60662512 .527 -2.8537513 .9266680 
3 -.15625000 .56162573 .999 -1.9062441 1.5937441 
4 -1.26950000 .56162573 .215 -3.0194941 .4804941 
5 -.00812500 .56162573 1.000 -1.7581191 1.7418691 
3 
dimension3 
1 -.80729167 .60662512 .678 -2.6975013 1.0829180 
2 .15625000 .56162573 .999 -1.5937441 1.9062441 
4 -1.11325000 .56162573 .323 -2.8632441 .6367441 
5 .14812500 .56162573 .999 -1.6018691 1.8981191 
4 
dimension3 
1 .30595833 .60662512 .986 -1.5842513 2.1961680 
2 1.26950000 .56162573 .215 -.4804941 3.0194941 
3 1.11325000 .56162573 .323 -.6367441 2.8632441 
5 1.26137500 .56162573 .219 -.4886191 3.0113691 
5 
dimension3 
1 -.95541667 .60662512 .535 -2.8456263 .9347930 
2 .00812500 .56162573 1.000 -1.7418691 1.7581191 
3 -.14812500 .56162573 .999 -1.8981191 1.6018691 
4 -1.26137500 .56162573 .219 -3.0113691 .4886191 
 
1=methanol, 2=acetone, 3=ethanol, 4=ethyl acetate, 5=ciprofloxacin 
89 
 
 
 
 
 
 
 
 
 
Multiple Comparisons FOR MBC of the extracts and the antibiotic 
MBC 
Tukey HSD 
(I) EXT (J) EXT Mean 
Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
d
i
m
e
n
s
i
o
n
2 
1 
dim
ens
ion
3 
2 -.0290548000 .0286896214 .845 -.118450040 .060340440 
3 .0103328000 .0286896214 .996 -.079062440 .099728040 
4 .0025831750 .0286896214 1.000 -.086812065 .091978415 
5 .0047738000 .0286896214 1.000 -.084621440 .094169040 
2 
dim
ens
ion
3 
1 .0290548000 .0286896214 .845 -.060340440 .118450040 
3 .0393876000 .0265614282 .589 -.043376310 .122151510 
4 .0316379750 .0265614282 .756 -.051125935 .114401885 
5 .0338286000 .0265614282 .711 -.048935310 .116592510 
3 
dim
ens
ion
3 
1 -.0103328000 .0286896214 .996 -.099728040 .079062440 
2 -.0393876000 .0265614282 .589 -.122151510 .043376310 
4 -.0077496250 .0265614282 .998 -.090513535 .075014285 
5 -.0055590000 .0265614282 1.000 -.088322910 .077204910 
4 
dim
ens
ion
3 
1 -.0025831750 .0286896214 1.000 -.091978415 .086812065 
2 -.0316379750 .0265614282 .756 -.114401885 .051125935 
3 .0077496250 .0265614282 .998 -.075014285 .090513535 
5 .0021906250 .0265614282 1.000 -.080573285 .084954535 
5 
dim
ens
ion
3 
1 -.0047738000 .0286896214 1.000 -.094169040 .084621440 
2 -.0338286000 .0265614282 .711 -.116592510 .048935310 
3 .0055590000 .0265614282 1.000 -.077204910 .088322910 
4 -.0021906250 .0265614282 1.000 -.084954535 .080573285 
 
1=methanol, 2=acetone, 3=ethanol, 4=ethyl acetate, 5=ciprofloxacin 
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Appendix 4 
Manuscripts in preparation 
1. Bioactivity and phytochemical analysis of Hydnora africana on some selected 
bacterial pathogens. 
2. Bioactivity of Hydonora africana on some selected bacterial pathogens: Preliminary 
phytochemical screening. 
 
